GSK Logo

site-logo

Are you a Healthcare Professional? Visit the Healthcare Professional website.

Zinnat

cefuroxime axetil

Product Overview

What is Zinnat?

Zinnat contains cefuroxime axetil, which is an antibiotic belonging to the cephalosporin class. Antibiotics are used to kill bacteria or “germs” which cause infection.

What is Zinnat used for?

Cefuroxime is used to treat infections in different parts of the body caused by bacteria. These include chest infections such as bronchitis and pneumonia, urinary tract infections, kidney infections, gonorrhoea (a sexually transmitted disease) and Lyme disease (an infection spread by ticks).

Formulations of Zinnat:

Zinnat is available in two formulations:

  • Zinnat Suspension 125mg/5ml – Each 5ml contains 125mg of the active substance cefuroxime (present as cefuroxime axetil).
  • Zinnat Tablets 125mg and 250mg – The active substance in each tablet is 125mg or 250mg of cefuroxime (present as cefuroxime axetil).

Who Can Take Zinnat?

  • Zinnat tablets are suitable for adults and children over 12 years of age who can swallow tablets.
  • The suspension is suitable for children under 12 years of age and for adults and children over 12 who may have difficulty in taking tablets.
  • Patients should take Zinnat as directed by their doctor.

For further information on Zinnat and potential side effects please see:

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.
Zinnat is a trade mark of the GlaxoSmithKline group of companies.

Rate the usefulness of this page

Rollover stars, click to select, then press submit.

P.O: Last updated 19 September 2012: UK/CFA/0002/12

Links & Resources

GSK does not recommend, endorse or accept liability for sites controlled by third-parties.